Government
The U.S. Food and Drug Administration (FDA) approved Incyte’s Pemazyre (pemigatinib) for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
Tukysa came out of Project Orbis, a multinational partnership between the FDA, the Australian Therapeutic Goods Administration, Health Canada, Health Sciences Authority and Swissmedic.
Here’s a look at what’s on the U.S. Food and Drug Administration’s schedule for the next two weeks.
The agency issued a statement saying that it will continue its activities, such as reviewing new drug applications and clinical trial, both COVID-19 and non-COVID-19, applications, “as we do everything possible to maintain continuity of operations in a very dynamic situation.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 17, 2020.
As Moderna moves forward with its mRNA vaccine candidate for COVID-19, the U.S. federal government is helping accelerate the potential medication with a $483 million infusion from the Biomedical Advanced Research and Development Authority.
Jelmyto is the first and only non-surgical treatment for patients with this indication. Here’s everything you need to know about it.
On Wednesday, U.S. District Judge Edward Davila set a new date of Oct. 27 to hear the criminal fraud case against Holmes and Theranos’ former president and her former boyfriend, Ramesh “Sunny” Balwani.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
Antibody tests, also called serological tests, test if the individual has been exposed to SARS-CoV-2, the novel coronavirus that causes COVID-19.
PRESS RELEASES